In two companion reports, the TRACERx consortium investigates tumor heterogeneity and evolution in early-stage non-small cell lung cancer. The studies highlight the prognostic value of copynumber heterogeneity assessment in tumor biopsies and circulating tumor DNA detection in plasma and suggest that tracking the evolution of lung cancers might aid clinical practice.
It is often stated that we have entered an era of precision cancer medicine. A salient example is that of metastatic oncogene-addicted non-small cell lung cancer (NSCLC), typically an affliction of non-smokers. For this type of cancer, it is now commonplace to tailor treatments of oral tyrosine kinase inhibitors (TKIs) to specific genetic alterations in kinases such as EGFR and ALK, in both the firstline and resistant settings (Lin and Shaw, 2016) . Despite these advances, metastatic lung cancer, even oncogene-addicted NSCLC, remains incurable. In the nonmetastatic setting, rates of recurrence after definitive treatment are high, and adjuvant platinum-based chemotherapy lends only a modest survival benefit (Pignon et al., 2008) . One hypothesis as to why lung cancer so readily evades therapy has to do with intratumor heterogeneity (ITH) and the evolution of genetically diverse tumor subclones. Two companion reports from the TRACERx consortium (TRAcking non-small cell lung Cancer Evolution through therapy [Rx] ), published recently in The New England Journal of Medicine and Nature, seek to assess the clinical impact of ITH and cancer genome evolution in early-stage NSCLC (JamalHanjani et al., 2017; Abbosh et al., 2017) .
In work by Jamal-Hanjani et al., resected NSCLC specimens from 100 treatment-naive patients enrolled in TRACERx were profiled by high-depth whole-exome sequencing. Multiple (R2) regions per lung tumor were sampled. The authors identified substantial ITH, with 30% of somatic mutations and 48% of somatic copy number alterations identified as subclonal. Tumors with a higher burden of subclonal copy-number alterations independent of tumor stage were associated with an increased likelihood of recurrence or death. ITH with respect to copy-number alterations (but not mutations) might thus represent a poor prognostic factor in NSCLC.
In early-stage NSCLC, surgical resection samples are sufficient to study ITH. However, in metastatic disease, when tumors have spread to distant sites, multiple biopsies would be needed to assess for ITH, which is neither safe nor feasible. In a companion report published in Nature, Abbosh et al. tracked lung cancer evolution non-invasively by circulating tumor DNA (ctDNA) detection in plasma (so-called ''liquid biopsies''). Studying the same TRACERx cohort, the authors synthesized patient-specific multiplex-PCR assay panels to follow both clonal and subclonal single nucleotide variants (SNVs) present in pre-operative plasma and at the time of recurrence. Pre-operatively, 48% of patients had R2 detectable SNVs in ctDNA. The median interval between ctDNA detection and relapse detected by CT imaging was 70 days, with four cases exhibiting a lead time of >6 months. The authors were also able to use ctDNA to trace the phylogenetic origin of the metastatic subclone.
How can we counter ITH and cancer genome evolution in the clinic (Figure 1) ? The inferred assumption is that clinical outcomes will be improved if tumors are less complex and less substrate for evolution is present. Capturing tumors prior to subclonal diversification requires earlier detection and screening. Imaging with low-dose chest CTs, which is currently the standard screening method, could be supplemented in the future with ctDNA, circulating tumor cell, serum protein biomarker, or exhaled volatile organic compound testing (Hasan et al., 2014) . Another approach could be to limit complexity by addressing the underlying mechanisms by which heterogeneity is generated. The TRACERx authors found that genome duplication was identified in 76% of tumors and was clonal in all but a few tumors, suggesting that it is an early event in tumor evolution (Jamal-Hanjani et al., 2017) . Moreover, they found that tumors with mutagenesis mediated by the cytidine deaminase APOBEC had the highest subclonal mutational burden. APOBEC3B depletion prolonged tamoxifen sensitivity, whereas, conversely, its overexpression accelerated resistance in a murine xenograft model of breast cancer (Law et al., 2016) . Therefore, inhibiting chromosomal instability early or APOBEC later in tumorigenesis could be possible strategies to prune tumor phylogenetic trees.
A third approach is to target truncal alterations essential to all tumor cells. Jamal-Hanjani et al. cataloged driver events and found that mutations in certain cancer genes such as EGFR, MET, and BRAF were not only clonal but occurred before genome duplication. The ability to target key driver mutations with TKIs has led to significant improvement in outcomes. Although these oncogene-addicted tumors have simpler phylogenetic trees, heterogeneity and drug-resistant subclones can exist even prior to treatment (Lin and Shaw, 2016) . Upfront use of broader spectrum TKIs could help address this heterogeneity. In patients with ALK-rearranged NSCLC, the J-ALEX trial demonstrated a significant prolongation in progression-free survival with alectinib, a second-generation ALK TKI with an extended spectrum of activity, including against the gatekeeper mutation, compared to the first generation 
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At time of diagnosis (A), ITH exists, allowing for tumor evolution both in the absence (B) and presence (D) of treatment. Early detection, targeting truncal mutations (C), or inhibiting underlying mechanisms by which heterogeneity is generated (E) are approaches to address ITH. Rationally sequencing therapies might allow us to predict and actively shape tumor evolution (F). ALK TKI crizotinib (Nokihara et al., 2016, Amer. Soc. Clin. Oncol., abstract). These findings suggest that clinical outcomes may be improved with use of upfront therapies that target as many subclones as possible.
A more difficult but intriguing mode of attack would be to shape cancer genome evolution actively. Again taking an example from ALK-rearranged NSCLC, a patient who had progressed on crizotinib due to a founder ALK C1156Y mutation responded to the third-generation ALK TKI lorlatinib. At relapse, this patient developed an additional ALK mutation (L1198F) that changed the exact residue used to enhance selectivity of lorlatinib (but not crizotinib) for ALK over other kinases. This mutation caused resistance to lorlatinib, but paradoxically restored sensitivity to crizotinib . While this was a fortuitous discovery, it inspires us to think that rational drug design and selection could allow us to sculpt tumor evolution.
The TRACERx studies are an exciting look into the future of precision oncology. Practically, however, there are several barriers to widespread implementation and adoption of these kinds of analyses. The first is cost. In the ctDNA study, the authors quote $1,750 per patient for sequencing of a single tumor region, synthesis of a PCR assay panel, and profiling of five plasma samples. Second, interpreting these data requires bioinformatics resources not readily available outside of major academic centers. Deploying this kind of testing without easily applicable analysis algorithms will be a significant bottleneck. A third barrier is the sensitivity of the sequencing platform. How much sampling and depth of sequencing will be required to represent any one individual's tumor? ctDNA detection should allow us to circumvent multiple biopsies. However, Abbosh et al. found that the lung tumor volume that correlated with a plasma variant allele fraction of 0.1%, the limit of confident detection with current ctDNA platforms, was 10 cm 3 .
Moreover, there are other inherent sampling biases that might skew heterogeneity analyses, given that tumors that do not shed ctDNA will not be adequately represented.
As our understanding of cancer biology becomes more nuanced, the metrics by which we assess tumor response will have to evolve accordingly. Particularly in the context of clinical trials, there is a need to incorporate novel biomarkers into our outcome measures (Neal et al., 2015) . Detection of resistant subclones by ctDNA might serve as an important endpoint, as well as provide an earlier opportunity to intervene. Ultimately, the goals of our treatments might not be simply to decrease the size of the tumor population as assessed by radiographic imaging, but also to change the characteristics of this heterogeneous population. Therapeutic interventions that can limit tumor heterogeneity and reshape tumor evolution might hold the key to improving cancer outcomes, including the most important outcome of survival.
